CTX-131

N/A

Report date: 2024/11/25 13:28:07

Base Information

Drug NameCTX-131
Drug Alias NameCTX-131
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsUterine Cervical NeoplasmsPancreatic NeoplasmsEsophageal Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesCrispr Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsPancreatic NeoplasmsEsophageal Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A